Philadelphia Trust Company’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$39.2M Sell
180,065
-1,917
-1% -$425K 2.76% 10
2025
Q4
$41.6M Sell
181,982
-3,741
-2% -$852K 2.87% 8
2025
Q3
$43M Sell
185,723
-7,371
-4% -$1.5M 3.03% 6
2025
Q2
$35.8M Sell
193,094
-2,615
-1% -$486K 2.75% 9
2025
Q1
$41M Sell
195,709
-14,378
-7% -$2.8M 3.51% 5
2024
Q4
$37.3M Buy
210,087
+2,322
+1% +$427K 2.74% 7
2024
Q3
$41M Buy
207,765
+702
+0.3% +$131K 2.98% 6
2024
Q2
$35.5M Buy
207,063
+1,379
+0.7% +$228K 2.76% 6
2024
Q1
$37.5M Buy
205,684
+12,597
+7% +$2.17M 3.01% 6
2023
Q4
$29.9M Sell
193,087
-2,290
-1% -$334K 2.81% 7
2023
Q3
$29.1M Sell
195,377
-10,426
-5% -$1.53M 2.99% 6
2023
Q2
$27.7M Sell
205,803
-4,520
-2% -$663K 2.62% 8
2023
Q1
$33.5M Sell
210,323
-15,858
-7% -$2.42M 3.41% 5
2022
Q4
$36.6M Sell
226,181
-21,304
-9% -$3.27M 3.91% 3
2022
Q3
$33.2M Buy
247,485
+26,169
+12% +$3.76M 3.76% 3
2022
Q2
$33.9M Sell
221,316
-20,000
-8% -$3.06M 3.48% 5
2022
Q1
$39.1M Sell
241,316
-12,931
-5% -$1.88M 3.09% 7
2021
Q4
$34.4M Sell
254,247
-13,896
-5% -$1.64M 2.49% 10
2021
Q3
$28.9M Sell
268,143
-3,254
-1% -$372K 2.13% 18
2021
Q2
$30.6M Sell
271,397
-3,825
-1% -$431K 2.11% 16
2021
Q1
$29.8M Sell
275,222
-1,072
-0.4% -$115K 2.29% 13
2020
Q4
$29.6M Buy
276,294
+2,015
+0.7% +$194K 2.41% 11
2020
Q3
$24M Buy
274,279
+45,500
+20% +$4.28M 2.32% 15
2020
Q2
$22.5M Buy
228,779
+205,516
+883% +$18.1M 2.37% 14
2020
Q1
$1.77M Sell
23,263
-68,890
-75% -$5.87M 0.22% 65
2019
Q4
$8.16M Buy
92,153
+18,065
+24% +$1.5M 0.7% 51
2019
Q3
$5.61M Buy
74,088
+57,517
+347% +$3.94M 0.52% 61
2019
Q2
$1.21M Buy
16,571
+865
+6% +$68K 0.11% 110
2019
Q1
$1.27M Sell
15,706
-650
-4% -$53.2K 0.11% 99
2018
Q4
$1.51M Sell
16,356
-1,021
-6% -$89.8K 0.16% 87
2018
Q3
$1.64M Sell
17,377
-338
-2% -$32.1K 0.13% 96
2018
Q2
$1.64M Sell
17,715
-175
-1% -$17.1K 0.15% 94
2018
Q1
$1.69M Sell
17,890
-891
-5% -$97.9K 0.14% 97
2017
Q4
$1.82M Sell
18,781
-360
-2% -$33.9K 0.14% 100
2017
Q3
$1.7M Buy
19,141
+200
+1% +$15.2K 0.14% 100
2017
Q2
$1.37M Sell
18,941
-83
-0.4% -$5.58K 0.12% 107
2017
Q1
$1.24M Buy
19,024
+350
+2% +$22K 0.1% 113
2016
Q4
$1.17M Buy
18,674
+575
+3% +$35.1K 0.09% 116
2016
Q3
$1.14M Buy
18,099
+115
+0.6% +$7.45K 0.1% 117
2016
Q2
$1.11M Sell
17,984
-360
-2% -$21.9K 0.1% 116
2016
Q1
$1.05M Sell
18,344
-1,075
-6% -$59.9K 0.09% 105
2015
Q4
$1.13M Sell
19,419
-2,290
-11% -$132K 0.09% 105
2015
Q3
$1.18M Buy
21,709
+20,394
+1,551% +$1.33M 0.11% 95
2015
Q2
$19.6K Sell
1,315
-18,364
-93% -$1.2M 0.07% 116
2015
Q1
$1.15M Sell
19,679
-60
-0.3% -$3.63K 0.09% 110
2014
Q4
$1.29M Sell
19,739
-145
-0.7% -$9.14K 0.1% 90
2014
Q3
$1.15M Sell
19,884
-30,240
-60% -$1.68M 0.07% 96
2014
Q2
$2.83M Sell
50,124
-299,588
-86% -$15.7M 0.18% 68
2014
Q1
$18M Sell
349,712
-412
-0.1% -$20.8K 1.13% 42
2013
Q4
$18.5M Buy
350,124
+4,496
+1% +$221K 1.18% 43
2013
Q3
$15.5M Buy
345,628
+4,871
+1% +$216K 1.07% 43
2013
Q2
$14.1M Buy
+340,757
New +$14.9M 1.06% 42

Other funds holding ABBV

Philadelphia Trust Company's ABBV Position: Q1 2026 in Review

Philadelphia Trust Company reduced its AbbVie (ABBV) stake by 1.1% in Q1 2026, selling an estimated $425K and leaving 180,065 shares worth $39.2M. The position accounts for 2.76% of the portfolio, ranked #10.

Philadelphia Trust Company first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $43M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • Philadelphia Trust Company held 180,065 shares of AbbVie worth $39.2M as of Q1 2026.
  • Philadelphia Trust Company sold 1,917 AbbVie shares in Q1 2026, an estimated $425K.
  • AbbVie made up 2.76% of Philadelphia Trust Company's portfolio in Q1 2026, its #10 holding.
  • Philadelphia Trust Company first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • Philadelphia Trust Company's AbbVie position peaked at $43M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Philadelphia Trust Company's 13F filing for Q1 2026, filed 13 May 2026.